Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

被引：0

作者：

Becker, Pamela S. ^{[1
]}

Medeiros, Bruno C. ^{[2
]}

Stein, Anthony Selwyn ^{[3
]}

Appelbaum, Frederick R. ^{[4
]}

Scott, Bart L. ^{[5
]}

Delaney, Colleen ^{[5
,6
]}

Othus, Megan

Hendrie, Paul C.

Gardner, Kelda M. ^{[5
]}

Petersdorf, Stephen ^{[7
]}

Pagel, John M.

Walter, Roland B. ^{[5
]}

Parks, Cynthia ^{[1
]}

Estey, Elihu H. ^{[5
]}

机构：

[1] Univ Washington, Div Hematol, Seattle, WA 98195 USA

[2] Stanford Comprehens Canc Ctr, Div Hematol, Stanford, CA USA

[3] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA USA

[4] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA

[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[6] UW, Dept Pediat, Seattle, WA USA

[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.3594.3594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3594

引用

页数：2

共 50 条

[11] Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, SingleArm Phase 2 Clinical Trial
Li, Xiaoping
Li, Xiaoyan
Jin, Yanling
Chen, Zucong
Shen, Yonglin
Yuan, Zhongtao
Liu, Lin
Li, Yu
Luo, Le
Hou, Shiqian
Zhou, Chaoyang
Qiu, Chie
Zhang, Kui
Li, Chunfu
Liang, Yang
Sanbin, Wang, Sr.
BLOOD, 2023, 142
[12] A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Godwin, Colin D.
Othus, Megan
Percival, Mary-Elizabeth M.
Hendrie, Paul C.
Scott, Bart L.
Appelbaum, Jacob S.
Halpern, Anna B.
Oehler, Vivian G.
Orozco, Johnnie J.
Keel, Sioban B.
Abkowitz, Janis L.
Cooper, Jason P.
Cassaday, Ryan D.
Orlowski, Kaysey F.
Marshall, Anise J.
Brown, Clarisa N.
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2021, 138
[13] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Bouligny, Ian M.
Kantarjian, Hagop M.
Yilmaz, Musa
Daver, Naval
Borthakur, Gautam
Dinardo, Courtney D.
Montalban-Bravo, Guillermo
Short, Nicholas J.
Valero, Yesid Alvarado
Jabbour, Elias
Jain, Nitin
Pemmaraju, Naveen
Hammond, Danielle
Chien, Kelly S.
Takahashi, Koichi
Issa, Ghayas C.
Abbas, Hussein A.
Garcia-Manero, Guillermo
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2024, 144 : 735 - 736
[14] A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Jabbour, Elias
Short, Nicholas J.
Ravandi, Farhad
Huang, Xuelin
Xiao, Lianchun
Garcia-Manero, Guillermo
Plunkett, William
Gandhi, Varsha
Sasaki, Koji
Pemmaraju, Naveen
Daver, Naval G.
Borthakur, Gautam
Jain, Nitin
Konopleva, Marina
Estrov, Zeev
Kadia, Tapan M.
Wierda, William G.
DiNardo, Courtney D.
Brandt, Mark
O'Brien, Susan M.
Cortes, Jorge E.
Kantarjian, Hagop
CANCER, 2017, 123 (22) : 4430 - 4439
[15] Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Godwin, Colin D.
Othus, Megan
Percival, Mary-Elizabeth M.
Scott, Bart L.
Becker, Pamela S.
Gardner, Kelda M.
Keel, Sioban B.
Dhawale, Tejaswini M.
Oehler, Vivian G.
Abkowitz, Janis L.
Halpern, Anna B.
Hendrie, Paul C.
Orlowski, Kaysey F.
Woo, Alice
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2019, 134
[16] Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
Zhu, Jun-Feng
Dai, Hai-Ping
Zhang, Qian-Qian
Yin, Jia
Li, Zheng
Cui, Qin-Ya
Tian, Xiao-Peng
Liu, Si-Ning
Jin, Zheng-Ming
Zhu, Xia-Ming
Wu, De-Pei
Tang, Xiao-Wen
FRONTIERS IN ONCOLOGY, 2022, 12
[17] Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Li, Jianyong
Chen, Yaoyu
Zhu, Yu
Zhou, Jianfeng
Xu, Yanli
Li, Yan
Yu, Kang
Pan, Ling
Wang, Jianmin
Ding, Jiahua
Gu, Jian
Zhou, Shanhua
Shi, Jinning
Hong, Ming
Xu, Ji
Pan, Liangqin
Duan, Limin
Zhang, Run
Zhang, Sujiang
Zhu, Huayuan
Lu, Hua
Liu, Peng
Qiu, Hongxia
Wu, Hanxin
Qian, Sixuan
ONCOTARGET, 2015, 6 (08) : 6448 - 6458
[18] EFFICACY AND SAFETY OF ETOPOSIDE IN COMBINATION WITH G-CSF, LOW-DOSE CYTARABINE AND ACLARUBICIN IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
Gao, L.
Feng, Y. M.
Yan, H. J.
Zhang, Y. Q.
Zhang, C.
Gao, L.
Kong, P. Y.
Liu, Y.
Zhu, L. D.
Zeng, Y. J.
Rao, J.
Su, Y.
Yang, T. H.
Wang, S. B.
Li, H. M.
Lou, S. F.
Zhang, X.
HAEMATOLOGICA, 2016, 101 : 387 - 387
[19] High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.
Powell, Bayard
D'Agostino, Ralph, Jr.
Levitan, Denise
Ellis, Leslie Renee
Lyerly, Susan
Skiles, Megan
Manuel, Megan
Harrelson, Robin
Kimbrough, Claire
Hurd, David Duane
BLOOD, 2008, 112 (11) : 676 - 676
[20] Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia
Xueya Zhang
Xizhe Guo
Annals of Hematology, 2019, 98 : 2223 - 2225

← 1 2 3 4 5 →